Education
About Us
Working with TipRanks
Follow Us
Compass Therapeutics (CMPX)
NASDAQ:CMPX
Total Valuation
Compass Therapeutics has a market cap or net worth of $384.43M. The enterprise value is $319.34M.
Market Cap$384.43M
Enterprise Value$319.34M
Share Statistics
Compass Therapeutics has 138,282,500 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding138,282,500
Owned by Insiders27.23%
Owned by Institutions0.04%
Financial Efficiency
Compass Therapeutics’s return on equity (ROE) is -0.39 and return on invested capital (ROIC) is -42.94%.
Return on Equity (ROE)-0.39
Return on Assets (ROA)-0.35
Return on Invested Capital (ROIC)-42.94%
Return on Capital Employed (ROCE)-0.43
Revenue Per Employee24.29K
Profits Per Employee-1.41M
Employee Count35
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Compass Therapeutics is -4.03. Compass Therapeutics’s PEG ratio is 0.58.
PE Ratio-4.03
PS Ratio0.00
PB Ratio3.21
Price to Fair Value1.59
Price to FCF-8.00
Price to Operating Cash Flow-8.01
PEG Ratio0.58
Income Statement
In the last 12 months, Compass Therapeutics had revenue of 850.00K and earned -49.38M in profits. Earnings per share was -0.36.
Revenue850.00K
Gross Profit850.00K
Operating Income-56.63M
Pretax Income-49.38M
Net Income-49.38M
EBITDA-54.87M
Earnings Per Share (EPS)-0.36
Cash Flow
In the last 12 months, operating cash flow was -44.17M and capital expenditures -62.00K, giving a free cash flow of -44.24M billion.
Operating Cash Flow-44.17M
Free Cash Flow-44.24M
Free Cash Flow per Share-0.32
Dividends & Yields
Compass Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.21
52-Week Price Change206.98%
50-Day Moving Average2.21
200-Day Moving Average2.11
Relative Strength Index (RSI)59.86
Average Volume (3m)813.07K
Important Dates
Compass Therapeutics upcoming earnings date is Jul 30, 2025, Before Open (Confirmed).
Last Earnings DateMay 8, 2025
Next Earnings DateJul 30, 2025
Ex-Dividend Date―
Financial Position
Compass Therapeutics as a current ratio of 14.96, with Debt / Equity ratio of 5.79%
Current Ratio14.96
Quick Ratio14.96
Debt to Market Cap0.00
Net Debt to EBITDA0.67
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Compass Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Compass Therapeutics EV to EBITDA ratio is -2.95, with an EV/FCF ratio of -3.61.
EV to Sales190.54
EV to EBITDA-2.95
EV to Free Cash Flow-3.61
EV to Operating Cash Flow-3.61
Balance Sheet
Compass Therapeutics has $112.64M in cash and marketable securities with $6.38M in debt, giving a net cash position of -$106.25M billion.
Cash & Marketable Securities$112.64M
Total Debt$6.38M
Net Cash-$106.25M
Net Cash Per Share-$0.77
Tangible Book Value Per Share$0.91
Margins
Gross margin is 100.00%, with operating margin of -6661.76%, and net profit margin of -5808.82%.
Gross Margin100.00%
Operating Margin-6661.76%
Pretax Margin-5808.82%
Net Profit Margin-5808.82%
EBITDA Margin-6455.53%
EBIT Margin-6661.76%
Analyst Forecast
The average price target for Compass Therapeutics is $13.20, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$13.20
Price Target Upside374.82% Upside
Analyst ConsensusStrong Buy
Analyst Count6
Revenue Growth Forecast―
EPS Growth Forecast-7.93%